| Literature DB >> 26268360 |
Megumi Fujiwara1, Nobuko Mori2, Touko Sato3, Hiroyuki Tazaki4, Shingo Ishikawa5, Ichiro Yamamoto6, Toshiro Arai7.
Abstract
BACKGROUND: Obesity and overweight have been frequently observed in dogs and cats in recent years as in humans. The compositions of fatty acids (FAs) in the accumulated lipids in tissues of obese animals may have important roles in the process and mechanisms related to the onset of metabolic disorders. The purpose of this study was to evaluate the effects of a high fat (HF) diet, which contained a higher proportion of saturated FAs, on FA metabolism and distribution in obese cats. Cats (N = 12) were divided into control diet group (crude fat; 16.0 %) (n = 4) or a high fat (HF) diet group (crude fat; 23.9 %) (n = 8). The HF diet contained up to 60 % of calories from fat and was rich in stearic acid. Blood samples were collected at 0, 2, 4 and 6 weeks after the feeding. Adipose and liver tissues were collected at the 6(th) week after feeding. We performed analysis of histological findings and fatty acid composition in serum and tissues.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26268360 PMCID: PMC4534048 DOI: 10.1186/s12917-015-0519-1
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Composition of nutrients and FA composition in control and HF diets
| Control | HF diet | ||
|---|---|---|---|
| Composition | Moisture (%) | 5.5 | 7.0 |
| Crude protein (%) | 33.6 | 32.7 | |
| Crude fat (%) | 16.0 | 23.9 | |
| Crude fiber (%) | 3.5 | 0.9 | |
| Crude ash (%) | 5.8 | 6.8 | |
| Nitrogen free extract (%) | 35.9 | 29.9 | |
| Kcal/g | 4.2 | 4.7 | |
| Composition of FAs | C16:0 (%) | 35.2 | 35.5 |
| C16:1 (%) | 7.0 | 4.9 | |
| C18:0 (%) | 14.4 | 25.0 | |
| C18:1n-9 (%) | 34.8 | 27.6 | |
| C18:2n-6 (%) | 5.7 | 5.0 | |
| C20:4n-6 (%) | 2.9 | 2.0 |
Fig. 1Average weekly food consumption of cats. Open bars: Control, Closed bars: High fat group
Changes in plasma biochemical parameters in cats fed a control or HF diet for 6 weeks
| Pre | 2 weeks | 4 weeks | 6 weeks | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cont ( | TP (g/dl) | 6.5 | ± | 0.4 | 6.4 | ± | 0.7 | 6.7 | ± | 6.8* | 7.0 | ± | 0.5* |
| AST (IU/l) | 26.5 | ± | 1.7 | 32.5 | ± | 3.7 | 29.0 | ± | 1.7 | 30.0 | ± | 1.8 | |
| TG (mg/dl) | 44.1 | ± | 17.3 | 49.5 | ± | 3.5 | 38.4 | ± | 7.0 | 50.0 | ± | 10.0 | |
| ALT (IU/l) | 52.0 | ± | 11.9 | 61.5 | ± | 5.7 | 65.0 | ± | 13.5 | 57.0 | ± | 11.4 | |
| ALP (IU/l) | 96.5 | ± | 29.4 | 170.0 | ± | 62.5**A | 114.5 | ± | 33.5A | 119.0 | ± | 40.3 | |
| LDH (IU/l) | 107.0 | ± | 25.3 | 116.5 | ± | 12.5 | 109.5 | ± | 80.0 | 112.0 | ± | 40.7 | |
| T-cho (mg/dl) | 106.0 | ± | 8.8 | 99.5 | ± | 8.0 | 116.0 | ± | 11.9 | 104.5 | ± | 8.7 | |
| Glu (mg/dl) | 76.5 | ± | 6.5 | 79.5 | ± | 3.9 | 79.5 | ± | 26.3 | 77.0 | ± | 1.3 | |
| BUN (mg/dl) | 23.5 | ± | 1.3 | 22.5 | ± | 1.7 | 22.5 | ± | 1.5 | 22.5 | ± | 1.7 | |
| Crea (mg/dl) | 0.7 | ± | 0.1 | 0.9 | ± | 0.2 | 0.9 | ± | 0.1 | 0.9 | ± | 0.1 | |
| NEFA (mEq/L) | 0.4 | ± | 0.0 | 0.5 | ± | 0.0 | 0.3 | ± | 0.1 | 0.5 | ± | 0.4* | |
| HF ( | TP (g/dl) | 6.5 | ± | 0.6 | 6.4 | ± | 0.6 | 6.5 | ± | 0.5 | 6.7 | ± | 0.5 |
| AST (IU/l) | 27.5 | ± | 4.5 | 30.5 | ± | 6.4* | 31.5 | ± | 5.6* | 32.0 | ± | 4.5** | |
| TG (mg/dl) | 44.1 | ± | 15.5 | 40.3 | ± | 19.8 | 40.3 | ± | 7.5 | 32.4 | ± | 29.7 | |
| ALT (IU/l) | 41.0 | ± | 14.2 | 59.5 | ± | 10.5 | 61.5 | ± | 12.7* | 70.5 | ± | 12.4** | |
| ALP (IU/l) | 77.0 | ± | 50.6 | 200.0 | ± | 16.2**BC | 112.0 | ± | 52.2B | 109.5 | ± | 55.0C | |
| LDH (IU/l) | 136.0 | ± | 46.3 | 122.0 | ± | 54.2 | 112.5 | ± | 46.4 | 126.5 | ± | 68.3 | |
| T-cho (mg/dl) | 104.0 | ± | 20.2 | 93.5 | ± | 21.4** | 98.0 | ± | 17.5 | 103.0 | ± | 29.1 | |
| Glu (mg/dl) | 73.0 | ± | 5.7 | 81.0 | ± | 7.8 | 84.5 | ± | 15.1** | 76.0 | ± | 10.6 | |
| BUN (mg/dl) | 23.5 | ± | 3.8 | 22.5 | ± | 2.2 | 23.5 | ± | 2.5 | 22.5 | ± | 2.3** | |
| Crea (mg/dl) | 0.8 | ± | 0.3 | 0.9 | ± | 0.2 | 1.0 | ± | 0.2 | 1.1 | ± | 0.2** | |
| NEFA (mEq/L) | 0.4 | ± | 0.1 | 0.4 | ± | 0.1 | 0.3 | ± | 0.1 | 0.6 | ± | 0.2* | |
Significantly different from Pre: *; P < 0.05 **; P < 0.01. The same capital letters indicate statistically significant differences between the time points (P < 0.05)
Fig. 2Histology of livers of cats after feeding. Hematoxylin and eosin (HE) staining of livers from the control group (a) and HF group (b). Oil red O staining of livers (c and d) revealed the accumulation of lipid droplets in hepatocytes in the HF group. Cells in Fig. 2a appeared to have greater steatosis than cells in Fig. 2b
FA composition in serum total FAs of cats fed a control or HF diet for 6 weeks
| Pre | 2 week | 4 week | 6 week | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | (%) | (%) | (%) | ||||||||||
| Control ( | C16:0 | 10.7 | ± | 1.1 | 9.5 | ± | 0.9 | 9.8 | ± | 1.1 | 10.5 | ± | 0.6 |
| C16:1n-7 | 6.6 | ± | 1.3 | 7.3 | ± | 0.3 | 7.1 | ± | 0.5 | 7.2 | ± | 0.4 | |
| C18:0 | 14.8 | ± | 0.9 | 16.1 | ± | 1.3 | 15.6 | ± | 1.1 | 14.5 | ± | 0.3a | |
| C18:1n-9 | 20.6 | ± | 3.2 | 20.8 | ± | 3.1 | 20.0 | ± | 2.4b | 19.8 | ± | 0.8c | |
| C18:2n-6 | 38.6 | ± | 2.3 | 38.5 | ± | 3.1 | 39.4 | ± | 4.2d | 40.5 | ± | 1.4e | |
| C20:4n-6 | 7.7 | ± | 0.3 | 7.3 | ± | 0.8 | 8.5 | ± | 2.1 | 6.7 | ± | 0.7f | |
| HF ( | C16:0 | 10.5 | ± | 0.6 | 10.1 | ± | 0.8 | 10.2 | ± | 0.8 | 10.8 | ± | 1.1 |
| C16:1n-7 | 5.9 | ± | 1.4 | 7.7 | ± | 2.7 | 6.4 | ± | 2.0 | 6.4 | ± | 1.7 | |
| C18:0 | 14.7 | ± | 1.0 | 14.9 | ± | 1.1 | 15.5 | ± | 0.7 | 15.5 | ± | 0.9*a | |
| C18:1n-9 | 18.8 | ± | 2.0 | 28.1 | ± | 3.4** | 25.1 | ± | 1.0**b | 24.6 | ± | 1.6**c | |
| C18:2n-6 | 34.4 | ± | 3.8 | 31.3 | ± | 4.7* | 32.0 | ± | 2.9*d | 31.0 | ± | 2.8**e | |
| C20:4n-6 | 12.2 | ± | 4.6 | 8.7 | ± | 1.4** | 11.2 | ± | 1.6 | 10.5 | ± | 2.0f | |
Significantly different from Pre: *; P < 0.05 **; P < 0.01. The same lowercase letters indicate statistically significant differences between the two groups (P < 0.05)
Changes in FA composition in total FAs in the liver of cats fed a control or HF diet
| Control ( | HF ( | |||||
|---|---|---|---|---|---|---|
| C16:0 (%) | 11.5 | ± | 1.5 | 13.8 | ± | 1.0 |
| C16:1n-7 (%) | 2.0 | ± | 0.1 | 1.4 | ± | 0.1 |
| C18:0 (%) | 20.5 | ± | 3.7 | 13.2 | ± | 0.1 |
| C18:1n-9 (%) | 13 | ± | 0.2 | 27.9 | ± | 3.3 |
| C18:2n-6 (%) | 39.2 | ± | 1.9 | 31.5 | ± | 1.6 |
| C20:4n-6 (%) | 13.8 | ± | 0.4 | 12.2 | ± | 0.7 |
Changes in FA composition in NEFAs in the serum of cats fed a control or HF diet
| Pre | 2 weeks | 4 weeks | 6 weeks | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | (%) | (%) | (%) | ||||||||||
| Control ( | C16:0 | 21.0 | ± | 1.0 | 20.0 | ± | 2.8 | 20.9 | ± | 1.8 | 21.5 | ± | 2.7 |
| C18:0 | 37.8 | ± | 1.6 | 32.9 | ± | 5.4 | 36.4 | ± | 2.3 | 39.8 | ± | 4.5 | |
| C18:1n-9 | 5.8 | ± | 0.4 | 5.7 | ± | 0.6a | 4.9 | ± | 0.5 | 4.8 | ± | 0.5b | |
| C18:2n-6 | 32.9 | ± | 0.9 | 39.4 | ± | 2.6** | 35.5 | ± | 1.0c | 32.7 | ± | 2.7 | |
| C20:4n-6 | 2.1 | ± | 0.3 | 1.6 | ± | 0.2 | 1.4 | ± | 0.3 | 1.1 | ± | 0.6 | |
| HF ( | C16:0 | 20.0 | ± | 2.5 | 18.8 | ± | 2.0AB | 22.8 | ± | 2.8A | 22.7 | ± | 5.2*B |
| C18:0 | 34.3 | ± | 2.2 | 37.4 | ± | 5.10 | 43.0 | ± | 3.1* | 36.5 | ± | 8.7 | |
| C18:1n-9 | 6.0 | ± | 0.6 | 8.7 | ± | 1.8**Ca | 5.8 | ± | 1.1CD | 8.2 | ± | 1.5**Db | |
| C18:2n-6 | 37.0 | ± | 2.1 | 33.8 | ± | 5.0 E | 28.3 | ± | 3.7**Ec | 30.2 | ± | 6.1** | |
| C20:4n-6 | 2.6 | ± | 1.0 | 1.7 | ± | 0.5** | 1.6 | ± | 0.5** | 1.8 | ± | 0.8** | |
Significantly different from Pre: *; P < 0.05 **; P < 0.01. The same capital letters indicate statistically significant differences between the time points (P < 0.05). The same lowercase letters indicate statistically significant differences between the two groups (P < 0.05)
Changes in FA composition in total FAs in the adipose tissue of cats fed a control or HF diet for 6 weeks
| Control ( | HF ( | ||||||
|---|---|---|---|---|---|---|---|
| SAT | C16:0 (%) | 27.0 | ± | 0.3 | 27.2 | ± | 1.5 |
| C16:1n-7 (%) | 0.3 | ± | 0.0 | 1.3 | ± | 1.5 | |
| C18:0 (%) | 12.3 | ± | 0.8 | 12.1 | ± | 0.1 | |
| C18:1n-9 (%) | 59.0 | ± | 0.8 | 57.9 | ± | 0.6 | |
| C18:2n-6 (%) | 1.0 | ± | 0.2 | 1.0 | ± | 0.4 | |
| C20:4n-6 (%) | 0.4 | ± | 0.1 | 0.3 | ± | 0.1 | |
| VAT | C16:0 (%) | 26.1 | ± | 0.6 | 26.1 | ± | 3.5 |
| C16:1n-7 (%) | 0.4 | ± | 0.1 | 0.4 | ± | 1.5 | |
| C18:0 (%) | 11.8 | ± | 2.0 | 11.8 | ± | 1.0 | |
| C18:1n-9 (%) | 60.6 | ± | 2.4 | 60.6 | ± | 3.5 | |
| C18:2n-6 (%) | 0.7 | ± | 0.1 | 0.7 | ± | 0.4 | |
| C20:4n-6 (%) | 0.4 | ± | 0.0 | 0.4 | ± | 0.1 | |
SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue